Propanc Biopharma Inc. (PPCB)
NASDAQ NASDAQ Primary Summary
PPCB Chart
People also search for
Propanc Biopharma Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Jae Cho Marex Group plc | 2,708.96 | $110,827 | $6,149.34 | -$104,677.66 | -94.45% |
Propanc Biopharma Inc. (PPCB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Propanc Biopharma Inc. ever had a stock split?
Propanc Biopharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | James Nathanielsz CEO | NASDAQ Exchange | 74346N800 CUSIP |
| AU Country | 1 Employees | - Last Dividend | 18 May 2026 Last Split | - IPO Date |
Overview
Propanc Biopharma, Inc. is an innovative biopharmaceutical company based in Camberwell, Australia, focused on developing novel cancer treatments. Established in 2007, the company primarily targets pancreatic, ovarian, and colorectal cancers, which represent areas of high unmet medical need. Propanc Biopharma, originally known as Propanc Health Group Corporation, rebranded itself in April 2017 to more accurately reflect its dedicated biopharmaceutical focus. The company is engaged in cutting-edge research and development, collaborating with prestigious institutions such as the University of Jaén and the University of Granada. Through these collaborations, Propanc Biopharma is not only advancing its proprietary drug discovery program, POP1, but also contributing to the broader understanding of cancer biology and potential therapeutic interventions.
Products and Services
Propanc Biopharma, Inc. offers a promising pipeline of cancer treatment candidates, with a primary focus on its lead product, PRP. Here's a closer look at their product offerings:
- PRP: A pioneering formulation that is currently in the preclinical phase of development. PRP is designed to harness the anti-cancer properties of several enzymes, enhancing their effects against cancer cells. This product exemplifies Propanc Biopharma's commitment to creating innovative treatments that address the complexities of cancer treatment, particularly for pancreatic, ovarian, and colorectal cancers.
In addition to developing its lead product, Propanc Biopharma is actively engaged in research collaborations that enrich its product development efforts:
- Research Collaboration with the University of Jaén: This partnership focuses on the POP1 joint drug discovery program. By collaborating with the University of Jaén, Propanc Biopharma leverages academic expertise and research capabilities to advance the development of novel cancer treatments.
- Joint Drug Discovery Program with Universities of Jaén and Granada: This collaborative effort aims to understand the changes in genetic and protein expression occurring in cancer cells. By combining the strengths of academic institutions and Propanc Biopharma's research team, this program seeks to unlock new pathways for cancer treatment, potentially leading to groundbreaking discoveries in the field.
